Investigação Clínica Prospectiva para Avaliar a Segurança e Desempenho do Juläine™ na Melhoria da Laxidez da Pele Glútea em Adultos.
Investigação Clínica Prospectiva para Avaliar a Segurança e o Desempenho do Ácido Poli-L-láctico - Juläine™ na Melhoria da Flacidez da Pele Glútea em Adultos.
This study aims to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) injections for the treatment of buttock skin laxity.
Participants will be randomized to an immediate-treatment group or a delayed-treatment group. The immediate-treatment group will receive 2 to 3 treatment sessions over up to 2 months and will be compared with the delayed-treatment group during the control period; the delayed-treatment group will receive the same treatment after the delay.
The primary objective is to assess clinical improvement in buttock skin elasticity 6 months after the last treatment, defined as an increase in skin elasticity measured by a cutometer. Total study participation is up to 16 months, including follow-up.
This multicenter trial will be conducted in Brazil.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This is an pivotal, open-label, two-arm, randomized, parallel-group, prospective clinical investigation conducted in Brazil to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) administered as subcutaneous injections for the treatment skin laxity in the buttock (gluteal) region in adults.
A total of 100 participants will be randomized to either an immediate-treatment group or a delayed-treatment group (delayed-start control). Participants in the immediate-treatment group will receive Juläine™ subcutaneous injections in 2 or 3 sessions at Day 0, Day 30, and Day 60. During this initial control period, outcomes in the immediate-treatment group will be compared with those in the delayed-treatment group, which will not receive treatment. After the control period, participants in the delayed-treatment group will receive the same Juläine™ regimen at Day 240, Day 270, and Day 300. Each participant will remain in the study for up to 16 months, excluding screening.
The primary efficacy endpoint is improvement in buttock skin elasticity 6 months after the last injection defined as an increase in global skin elasticity measured by a cutometer, with assessments at screening/baseline and at the primary post-treatment timepoint. The mean change in global skin elasticity measured by cutometer and Global Aesthetic Improvement Scale (GAIS) will also be evaluated, comparing groups during the control period.
Safety will be monitored through the collection of adverse events (AEs) through 240 days after randomization, with comparisons between groups during the control period. Adverse events will also be evaluated through extended follow-up, including up to 180 days in the overall study population and up to 480 days in the immediate-treatment group.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adults aged 18 to 55 years;
- Body Mass Index (BMI) between 18.5 and 24.95 kg/m².
- Skin laxity of the gluteal region defined as sagging and reduced tightness of the skin.
- Women of childbearing potential must be willing to abide by the contraceptive requirements
- Ability to understand the study and provide informed consent, attend follow-up visits, and follow post-injection instructions.
Exclusion Criteria:
- Pregnancy or breastfeeding, or planned pregnancy/lack of adequate contraception (through 8 weeks post-study);
- Is planning to donate/bank or retrieve eggs (ova, oocytes) or donate sperm during the study or within 8-weeks of the end of participation of the clinical investigation.
- Active infection, inflammation or lesions at or near the treatment site.
- Acute infection at screening;
- History of autoimmune disease;
- Immune deficiencies;
- History of hypertrophic scarring or keloid formation;
- History of thrombosis in the lower limbs.
- Previous surgical procedures involving the buttocks
- Previous treatment with fillers, suspension threads, or fat injection in the treatment area within 18 months before randomization.
- Previous aesthetic procedures in the treatment area, including radiofrequency, ultrasound, cryotherapy, neurotoxin, laser or light treatment, or chemical peel, within six months before randomization.
- Previous topical or home therapy for cellulite in the treatment area within three months before randomization.
- Hemorrhagic disease or ongoing use of antiplatelets/anticoagulant therapy.
- Treatment with chemotherapy, immunosuppressive agents, systemic corticosteroids within 3 months before treatment (inhaled or ophthalmic corticosteroids are allowed).
- Use of hormonal replacement therapy (HRT) unless the participant has been on a stable dose for at least 3 months prior to screening and does not plan to make any changes to the HRT regimen during the study period.
- Use of topical corticosteroids, topical prescription retinoids in the treatment area within 1 month of the Baseline visit or systemic retinoid treatment within 6 months of the baseline visit, or plan to receive such treatment.
- Use of other agents that inhibit collagen production.
- Known allergy or hypersensitivity to any component of the investigational product.
- History of herpes simplex rashes, malignant skin diseases, or any other serious dermatologic or systemic disease.
- Presence of any condition that may impair wound healing (e.g., connective tissue disorders, severe malnutrition).
- Planned or ongoing cosmetic procedures involving the buttocks or surrounding area during the period of clinical investigation.
- Presence of any skin or local condition in the treatment area that could interfere with treatment administration, participant safety, or evaluation of study endpoints, including scars, fibrosis, tattoos, skin-pigmentation alterations, inflammation, lymphedema, or lipedema.
- Participants actively taking GLP-1 medications with the intention of achieving additional weight loss (expected >10% during study) will be excluded. Participants on a stable GLP-1 regimen (≥3 months) for diabetes management or weight maintenance, with documented weight stability (±10% in past 6 months) and no planned or expected weight change >10%, may be included.
- Any other medical or psychological condition that, in the opinion of the investigator, may interfere with participation in clinical research or evaluation of results.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Grupo de tratamento imediato
|
Juläine™ is a sterile injectable medical device composed of polylactic acid microspheres. |
|
Outro: Grupo de tratamento diferido (controlo de início diferido)
|
Juläine™ is a sterile injectable medical device composed of polylactic acid microspheres. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of participants who achieve an improvement in gluteal skin elasticity
Prazo: Baseline and 240 days after randomization
|
Proportion of participants achieving a clinically significant reduction in gluteal skin laxity at Day 240 after randomization, whereby a clinically significant reduction ("response") is defined as a relative increase of at least 10% in the gross elasticity measured by cutometer at Day 240 compared to baseline. |
Baseline and 240 days after randomization
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean change in overall skin elasticity
Prazo: Baseline and Day 240 after randomization.
|
Mean change in global medial skin elasticity measured by cutometer 180 days after treatment completion. |
Baseline and Day 240 after randomization.
|
|
Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by investigator
Prazo: Baseline and Day 240 after randomization.
|
Proportion of participants with at least a 1-point improvement in GAIS as rated by the investigator at Day 240 after randomization. The GAIS scale values are:
Where 1 represents the best outcome and 5 represents the worst. |
Baseline and Day 240 after randomization.
|
|
Global improvement based on Global Aesthetic Improvement Scale (GAIS) evaluated by participant
Prazo: Baseline and Day 240 after randomization.
|
Proportion of participants with at least a 1-point improvement in GAIS as rated by the participant at Day 240 after randomization The GAIS scale values are:
Where 1 represents the best outcome and 5 represents the worst. |
Baseline and Day 240 after randomization.
|
|
Proportion of adverse events (AEs)
Prazo: Occurring up to 240 days after the start of treatment, in both groups.
|
Proportion of adverse events (AEs) occurring up to 240 days after randomization. |
Occurring up to 240 days after the start of treatment, in both groups.
|
|
Incidence and severity of Adverse events in the first 30 days
Prazo: First 30 days after each Juläine™ administration, in all treated participants.
|
Incidence and severity of Adverse events in the first 30 days after each Juläine™ administration, in all treated participants. |
First 30 days after each Juläine™ administration, in all treated participants.
|
|
Incidence and severity of AEs up to 240 days.
Prazo: Up to 240 days after start of treatment in all treated participants.
|
Incidence and severity of AEs up to 240 days after start of treatment in all treated participants. |
Up to 240 days after start of treatment in all treated participants.
|
|
Incidence and severity of AEs up to 480 days
Prazo: Up to 480 days after start of treatment in the immediate-start group.
|
Incidence and severity of AEs up to 480 days after start of treatment in the immediate-start group. |
Up to 480 days after start of treatment in the immediate-start group.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- NB 15-TF-BZ-100-08F
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .